DCCT : medical and economical message, five years later.
Insulin : State of the Art. International Scientific Symposium. Frankfurt/M, DEU, 1998/10/24.
Diabetes Control and Complication Trial (DCCT) was a landmark study in the annals of diabetes research.
It did firmly establish the importance of achieving near normal glycemia in prevention and/or delay in onset and progression of microangiopathic complications.
However, over the last five years since its initial publication, several questions have arisen, especially in terms of long-term medical impact of a higher daily dose of insulin required with intensive therapy, i.e., advent of overt obesity ; increasing waist/hip ratios and their potential adverse effects such as hypertension, dyslipidemia and macrovascular disease ; necessity of tight control in all diverse populations of diabetes, and the need for intensive therapy for the total duration of diabetes.
Moreover, the applicability of DCCT recommendations to subjects with both types is being better accepted worldwide than ever before.
Finally, DCCT may have led to zealous efforts in possible prevention and early detection of the disease as well as prompt implementation of appropriate therapeutic strategies to achieve optimal control and further investigation into newer tools for blood glucose monitoring methods of insulin administration and insulin formulations. (...)
Mots-clés Pascal : Diabète, Essai clinique, Impact économique, Economie santé, Complication, Prévention, Etats Unis, Amérique du Nord, Amérique, Homme, Endocrinopathie, DCCT
Mots-clés Pascal anglais : Diabetes mellitus, Clinical trial, Economic impact, Health economy, Complication, Prevention, United States, North America, America, Human, Endocrinopathy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0299760
Code Inist : 002B21E01B. Création : 16/11/1999.